Determine the necessary mass, volume, or concentration for preparing a solution.
This is a demo store. No orders will be fulfilled.
| SKU | Size | Availability |
Price | Qty |
|---|---|---|---|---|
|
Ab182990-100μg
|
100μg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$59.90
|
|
|
Ab182990-1mg
|
1mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$289.90
|
|
|
Ab182990-5mg
|
5mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$749.90
|
|
|
Ab182990-10mg
|
10mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$1,189.90
|
|
Purity≥95% (SDS-PAGE&SEC); Endotoxin Level≤1.0EU/mg; Human IgG4SP; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
| Product Name | Tifcemalimab (anti-BTLA) - Primary antibody, specific to BTLA, Human IgG4SP |
|---|---|
| Synonyms | B and T lymphocyte attenuator antibody | B and T lymphocyte associated protein antibody | B and T lymphocyte associated antibody | B- and T-lymphocyte attenuator antibody | B- and T-lymphocyte-associated protein antibody | JS004 | MGC129743 | BTLA antibod |
| Specifications & Purity | Carrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, Animal Free, ≥95%(SDS-PAGE&SEC-HPLC), See COA |
| Biochemical and Physiological Mechanisms | Lymphocyte inhibitory receptor which inhibits lymphocytes during immune response. Post-translational: Phosphorylated on Tyr residues by TNFRSF14 and by antigen receptors cross-linking, both inducing association with PTPN6 and PTPN11. N-glycosylated. |
| Host species | Human |
| Specificity | BTLA |
| Conjugation | Unconjugated |
| Grade | Animal Free, Azide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated |
| Product Description |
Tifcemalimab (anti-BTLA) is a humanized anti-BTLA (B and T lymphocyte attenuation factor) monoclonal antibody. Tifcemalimab (anti-BTLA) blocks the interaction of HVEM-BTLA by binding to BTLA, and thus blocks the inhibitory signaling pathway mediated by BTLA. Tifcemalimab (anti-BTLA) can be used in research of cancer.
|
| Isotype | Human IgG4SP |
|---|---|
| Light Chain Type | kappa |
| SDS-PAGE | 146 kDa |
| Purification Method | Protein A purified |
| Concentration | See COA |
| Storage Temp | Store at -80°C,Avoid repeated freezing and thawing |
| Shipped In | Ice chest + Ice pads |
| Stability And Storage | Store at -80℃ for 24 months. Upon receipt, it is recommended to aliquot. Avoid freeze/thaw cycle. |
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
Tifcemalimab (anti-BTLA) (Ab182990) - Flow Cytometry
Flow Cytometry analysis of human peripheral blood lymphocytes labelling BTLA with Tifcemalimab (anti-BTLA) (Ab182990) conjugated with biotin (right panel) compared with Human IgG (Biotin) (Ab180314) - Isotype Control (left panel) and detected with SA-PE (rp156150).
Tifcemalimab (anti-BTLA) (Ab182990) - Flow Cytometry
Flow Cytometry analysis of human peripheral blood lymphocytes labelling BTLA (red) with Tifcemalimab (anti-BTLA) (Ab182990) conjugated with biotin and detected with SA-PE (rp156150). Blue - Isotype control, Human IgG (Biotin) (Ab180314). Black - Unlabelled control, cells without incubation with primary antibody.
Tifcemalimab (anti-BTLA) (Ab182990) - ELISA
Immobilized Recombinant Human BTLA protein (rp143904) at 1.0 μg/mL can bind Tifcemalimab (anti-BTLA) (Ab182990) with the EC₅₀ of 130.30 ng/mL.
Tifcemalimab (anti-BTLA) (Ab182990) - SEC
The purity of Tifcemalimab (anti-BTLA) (Ab182990) is more than 95% verified by HPLC.
Starting at $109.90